OPTIRAY 350 Drug Patent Profile
✉ Email this page to a colleague
When do Optiray 350 patents expire, and what generic alternatives are available?
Optiray 350 is a drug marketed by Liebel-flarsheim and is included in two NDAs.
The generic ingredient in OPTIRAY 350 is ioversol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ioversol profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OPTIRAY 350?
- What are the global sales for OPTIRAY 350?
- What is Average Wholesale Price for OPTIRAY 350?
Summary for OPTIRAY 350
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 73 |
| Clinical Trials: | 3 |
| Patent Applications: | 1,841 |
| DailyMed Link: | OPTIRAY 350 at DailyMed |
Recent Clinical Trials for OPTIRAY 350
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Guerbet/Liebel-Flarsheim | Phase 4 |
| Duke Clinical Research Institute | Phase 4 |
| GE Healthcare | Phase 4 |
Pharmacology for OPTIRAY 350
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for OPTIRAY 350
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liebel-flarsheim | OPTIRAY 350 | ioversol | INJECTABLE;INJECTION | 019710-005 | Jan 22, 1992 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Liebel-flarsheim | OPTIRAY 350 | ioversol | INJECTABLE;INJECTION | 020923-003 | May 28, 1998 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OPTIRAY 350
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Liebel-flarsheim | OPTIRAY 350 | ioversol | INJECTABLE;INJECTION | 019710-005 | Jan 22, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Liebel-flarsheim | OPTIRAY 350 | ioversol | INJECTABLE;INJECTION | 020923-003 | May 28, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OPTIRAY 350
See the table below for patents covering OPTIRAY 350 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 3362967 | ⤷ Sign Up | |
| Netherlands | 930067 | ⤷ Sign Up | |
| Australia | 9151182 | ⤷ Sign Up | |
| Canada | 1198739 | DERIVES DE 2,4,6-TRIIODOISOPHTALAMIDE (2,4,6-TRIIODOISOPHTHALAMIDE DERIVATIVE) | ⤷ Sign Up |
| Australia | 552188 | ⤷ Sign Up | |
| Japan | H0224252 | ⤷ Sign Up | |
| Japan | S58131970 | COMPOUND | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OPTIRAY 350
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0083964 | 93C0142 | Belgium | ⤷ Sign Up | PRODUCT NAME: IOVERSOL; NAT. REGISTRATION NO/DATE: 74 IS 56 F12/19910521; FIRST REGISTRATION: NL RVG 13345 19891016 |
| 0083964 | SPC/GB93/089 | United Kingdom | ⤷ Sign Up | SPC/GB93/089: 20041015 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
